Oscotec Inc.

Translating science into medicine
회원가입
PRESS
  1. No Image 01Jun
    by

    Profiles of Four New Stock-Billionaires

  2. No Image 01Jun
    by

    Oscotec shares rebound on launch of US clinical trial

  3. No Image 01Jun
    by

    Oscotec`s acute leukemia treatment wins orphan drug status from FDA

  4. No Image 01Jun
    by

    Oscotec wins exception policy for continued R&D for new drugs

  5. No Image 01Jun
    by

    Yuhan to start phase-3 trial on lung cancer drug Lazertinib

  6. No Image 03Mar
    by

    Oscotec and Beactica Therapeutics announce license and collaboration agreement to develop new cancer drug

  7. No Image 01Jun
    by

    Abstract 2010 : SKI-G-801, an AXL kinase inhibitor, blocks metastasis and induces anti-tumor immune response in various syngeneic cancer models

  8. No Image 01Jun
    by

    Genosco/Yuhan Announce Results from Phase 1/2 Study of YH25448, a 3rd-Generation EGFR-TKI, in Advanced NSCLC to be Presented at ASCO 2018

  9. No Image 01Jun
    by

    "ASCO 2018: Genosco/Yuhan Announce Results from Phase 1/2 Study of Lazertinib (YH25448, GNS-1480), a 3rd-Generation EGFR-TKI, in Advanced NSCLC"

  10. No Image 01Jun
    by

    Korea`s Yuhan Licenses out Lung Cancer Treatment to Janssen Biotech

  11. No Image 03Mar
    by

    Other news to note for March 2, 2021

  12. No Image 01Jun
    by

    Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring Exon 20 Insertion Mutations

Board Pagination Prev 1 2 3 Next
/ 3
© k2s0o1d6e0s8i2g7n. ALL RIGHTS RESERVED.
서버에 요청 중입니다. 잠시만 기다려 주십시오...